MARKET

GALT

GALT

Galectin Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.310
+0.050
+3.97%
Closed 16:00 05/26 EDT
OPEN
1.270
PREV CLOSE
1.260
HIGH
1.420
LOW
1.270
VOLUME
46.09K
TURNOVER
44.85K
52 WEEK HIGH
4.400
52 WEEK LOW
1.190
MARKET CAP
77.80M
P/E (TTM)
-2.2578
1D
5D
1M
3M
1Y
5Y
Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress
NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the H.C. Wainwright Global Investment Conferen...
GlobeNewswire · 3d ago
Galectin Therapeutics GAAP EPS of -$0.17
Galectin Therapeutics press release (NASDAQ:GALT): Q1 GAAP EPS of -$0.17. The company had $31.6M of cash and cash equivalents, which is sufficient to fund currently planned operations and research and development activities
Seekingalpha · 05/16 12:49
Recap: Galectin Therapeutics Q1 Earnings
  Galectin Therapeutics (NASDAQ:GALT) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/16 12:29
BRIEF-Galectin Therapeutics Inc - QTRLY Loss Per Share $0.17
reuters.com · 05/16 12:25
BRIEF-Galectin Therapeutics Reports Financial Results For The Quarter Ended March 31
reuters.com · 05/16 12:14
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.
Zacks · 05/11 15:20
Nano Dimension’s Preliminary Q1/2022 Revenues: Approximately $10.5 Million
39% Increase Over Q4/2021 and 1,195% Increase Over Q1/2021Waltham, Massachusetts, May 03, 2022 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (“Nano Dimension” or the “Company”) (Nasdaq: NNDM), an industry-leader in Additively Manufactured Electronics (AME), Prin...
GlobeNewswire · 05/03 12:30
More
No Data
Learn about the latest financial forecast of GALT. Analyze the recent business situations of Galectin Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GALT stock price target is 11.00 with a high estimate of 11.00 and a low estimate of 11.00.
High11.00
Average11.00
Low11.00
Current 1.310
EPS
Actual
Estimate
-0.15-0.11-0.08-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 85
Institutional Holdings: 8.64M
% Owned: 14.54%
Shares Outstanding: 59.39M
TypeInstitutionsShares
Increased
15
445.39K
New
6
113.41K
Decreased
11
87.61K
Sold Out
19
377.96K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Richard Uihlein
President/Chief Executive Officer/Director
Joel Lewis
Chief Financial Officer
Jack Callicutt
Executive Vice President
Eliezer Zomer
Vice President
J. Rex Horton
Other
Pol Boudes
Director
Harold Shlevin
Independent Director
Gilbert Amelio
Independent Director
James Czirr
Independent Director
Kary Eldred
Independent Director
Kevin Freeman
Independent Director
Gilbert Omenn
Independent Director
Marc Rubin
Independent Director
Elissa Schwartz
Independent Director
Richard Zordani
No Data
No Data
About GALT
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.

Webull offers kinds of Galectin Therapeutics Inc stock information, including NASDAQ:GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.